Brain Protein Expression Profile of Semax in a Rat Model of Cerebral Ischemia–Reperfusion
Animal research · 2021
- What was studied
- Male Wistar rats. Figures 2–3 report 5–7 animals per group for Western blots.
- Main finding
- At 24 hours in a rat ischemia model, Semax lowered activated JNK in two brain regions and raised activated CREB in the subcortex by more than 1.5-fold.
Reported findings and study design
A 90-minute middle cerebral artery occlusion followed by reperfusion. The investigators compared Semax-treated rats, saline-treated rats with ischemia, and a saline-treated sham group. Protein analysis used animals with MRI-confirmed subcortical lesions in the ischemia groups.
Population or model Male Wistar rats. Figures 2–3 report 5–7 animals per group for Western blots.
Dose, route and schedule
100 μg/kg intraperitoneal Semax per injection, first immediately after artery occlusion and again 1.5 and 5 hours after reperfusion began. Control groups received saline at the same time points.
Protocol source ↗ · Original article, methods and Figures 2–3
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Activated JNK | Over two-fold higher after ischemia than sham and more than 1.5-fold lower with Semax than with saline after ischemia | Subcortex and adjacent frontoparietal cortex · 24 hours after occlusion · p<0.05, Figure 2 |
| Activated CREB | More than 1.5-fold higher with Semax than with saline after ischemia | Subcortex. The cortical change was not statistically significant. · 24 hours after occlusion · p<0.05, Figure 2 |
| MMP-9 and c-Fos protein | Each fell by more than 1.5-fold with Semax compared with the saline ischemia group | Frontoparietal cortex. No significant treatment difference in subcortex. · 24 hours after occlusion · p<0.05, Figure 3 |
The experiment measures four selected proteins at one time point in a rat model. It provides no human treatment outcomes.
Source for these results ↗ · Reviewed 2026-11-16
Study limitations and source details
Study limitations
- Animal molecular endpoints do not demonstrate clinical stroke efficacy.
- Related transcriptomic and protein studies are not automatically independent replication.
Source details
Journal publication
Original article, methods and Figures 2–3
Sources checked
Citation
Olga Yu Sudarkina, Ivan B Filippenkov, Vasily V Stavchansky, Alina E Denisova, Vadim V Yuzhakov, Larisa E Sevankaeva, Liya V Valieva, Julia A Remizova, Veronika G Dmitrieva, Leonid V Gubsky, Nikolai F Myasoedov, Svetlana A Limborska, Lyudmila V Dergunova. Brain Protein Expression Profile of Semax in a Rat Model of Cerebral Ischemia–Reperfusion Int J Mol Sci. 22(12):6179
Study source ↗ · DOI 10.3390/ijms22126179 · Bibliography entry · Link to this summary